RNAC selectabio.com Company Net Income

Corporate emblem and logo of selectabio.com (RNAC)

This daily price chart for Cartesian Therapeutics (RNAC) on the GURU.Markets platform demonstrates the -0.15 metric. Cartesian Therapeutics enjoys well-deserved recognition within the scientific community and a high level of confidence from investors. The business is based on creating innovative RNA-based therapies, while the cash flow is fueled by licensing fees from industry behemoths and the treatment of patients with severe pathologies.

RNAC Cartesian Therapeutics, Inc.: Net Income in the range 02/21/2024 - 10/29/2026

Financial and market metric breakdowns for Cartesian Therapeutics, Inc. (RNAC)

- share price and consensus valuation forecast:
Price Chart Selecta Biosciences Inc.|RNAC - Price Target Chart
- market capitalization data:
Market Value Selecta Biosciences Inc.|RNAC - Enterprise Value
- balance sheet equity data:
Book Value of One Share Cartesian Therapeutics|RNAC - Company Net Assets|Market-to-Book Ratio selectabio.com|RNAC - Cumulative Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Cartesian Therapeutics|RNAC - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Selecta Biosciences|RNAC - Company Aggregate Debts|Debts to Book Value Selecta Biosciences Inc.|RNAC - Company Long-Term Debt|Company Short-Term Debt Cartesian Therapeutics|Quick Liquidity selectabio.com
- business earnings and investment ratios data:
RNAC - Net Income
Fundamental valuation:RNAC Selecta Biosciences Inc.
Manufactured products of Cartesian Therapeutics Inc

Investors are searching the Cartesian Therapeutics (RNAC) financial statements for sustainable fundamental pillars to assess asset value. This indicator uses stress testing to strip the financial result of one-off market distortions, revealing the business's real margin of safety. An analysis of the company's quarterly profit allows for the timely identification of deep drawdown risks. For Cartesian Therapeutics, this metric reflects the monetization efficiency of grants and RNA partnerships. The stability of this indicator confirms the viability of the cell-based biopharmaceutical development strategy.

Main competitors

LEGN (Legend Biotech Corp.) - Company Net Income|Company Net Income Sana Biotechnology|Company Net Income autolus.com AUTL|Net Profit ALLO|cellectis.com (CLLS) - Annual Net Income|Caribou Bio - Net Income|Instil Bio Inc (TIL) - Company Net Income|GNTA: Net Income|Final Profit IPSC (Century Therapeutics)|JSPR: Net Profit|Net Income Senti Biosciences|ADAP (Adaptimmune Therapeutics plc) - Net Profit|Company Net Income CERo Therapeutics Holdings Inc. CERO|Company Net Income Alaunos Therapeutics (TCRT)|Company Net Income ACHL (achillestx.com)|Company Net Income CARGO Therapeutics, Inc. CRGX|Poseida Therapeutics Inc - Company Net Income|TSVT: Net Income|Final Profit GRCL (Gracell)